Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8493097 | 0.88 | CA12 (0.66) | LMNACA12CA1CA2CA7 | |
| SCHEMBL1996045 | 0.88 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29723948 | 0.84 | ALDH1A1 (0.47) | LMNARAB9ANPC1ALDH1A1GAA | |
| SCHEMBL10441996 | 0.84 | ALDH1A1 (0.47) | LMNARAB9ANPC1ALDH1A1GAA | |
| SCHEMBL10562280 | 0.83 | CA12 (0.59) | LMNACA12CA1CA2CA7 | |
| SCHEMBL28391542 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6640647 | 0.81 | ALDH1A1 (0.45) | LMNARAB9AALDH1A1GAAMAPT | |
| SCHEMBL2339088 | 0.81 | CA12 (0.79) | LMNACA12CA1CA2CA7 | |
| SCHEMBL4625647 | 0.81 | TSHR (0.61) | LMNACA12CA1CA2CA7 | |
| SCHEMBL20899341 | 0.81 | CA12 (0.79) | LMNACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | disclosed |
| US-9439890-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-09-13 | — | — | US | disclosed |
| EP-2718284-B1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-11-18 | — | — | EP | disclosed |
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2015-10-08 | — | — | US | disclosed |
| US-9096545-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-08-04 | — | — | US | disclosed |
| EP-2718284-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2013118071-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013038308-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-03-21 | — | — | WO | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGIS, PTGS1 | LMNA 3938/4885CA12 4857/4885CA1 3662/4885 |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LMNA 3409/4885CA12 4331/4885CA1 1821/4885 |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LMNA 4091/4885CA12 4830/4885CA1 2987/4885 |
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | LMNA 2939/4885CA12 4066/4885CA1 2741/4885 |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LMNA 4091/4885CA12 4830/4885CA1 2987/4885 |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | PTGES, PTGS1, PTGIS | LMNA 4091/4885CA12 4830/4885CA1 2987/4885 |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | LMNA 4091/4885CA12 4830/4885CA1 2987/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | LMNA 4091/4885CA12 4830/4885CA1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.